» Articles » PMID: 19054170

Bladder Cancer Develops 6 Years Earlier in Current Smokers: Analysis of Bladder Cancer Registry Data Collected by the Cancer Registration Committee of the Japanese Urological Association

Overview
Journal Int J Urol
Specialty Urology
Date 2008 Dec 5
PMID 19054170
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: It is generally recognized that cigarette smoking is the most important risk factor for bladder cancer. The present study was undertaken to examine the relationships between smoking history of bladder cancer patients and the age of onset of bladder cancer and tumor characteristics.

Methods: The present study examined the data for 5959 cases (4728 males and 1231 females) collected in the bladder cancer database of the Japanese Urological Association from 1999 to 2001. Patients were divided by smoking history into three categories as current non-smokers, current smokers and unknown smoking history. Relationship between smoking history and the age at diagnosis of bladder cancer, gender, T stage, grade, tumor size, tumor number and initial symptoms was analyzed.

Results: In both males and females the onset of bladder cancer is about 6 years (6.1 years in males and 5.9 years in females) earlier for current smokers than for current non-smokers. At the time of diagnosis, tumor stage was significantly higher in the current smokers group. The current smokers group tended to have larger tumor size.

Conclusions: The finding of 6-year-earlier onset of bladder cancer among current smokers is of great importance to both health care and medical economics. It is essential to make people better informed concerning the need to quit smoking.

Citing Articles

Silencing the Mitochondrial Gatekeeper VDAC1 as a Potential Treatment for Bladder Cancer.

Alhozeel B, Pandey S, Shteinfer-Kuzmine A, Santhanam M, Shoshan-Barmatz V Cells. 2024; 13(7.

PMID: 38607066 PMC: 11012128. DOI: 10.3390/cells13070627.


Risk Factors for Bladder Cancer: Results of a Survey of Hospital Patients.

Shadab R, Nerli R, Bidi S, Ghagane S J Cancer Allied Spec. 2023; 9(1):485.

PMID: 37197001 PMC: 10187602. DOI: 10.37029/jcas.v9i1.485.


Long non-coding RNA SNHG1 promotes bladder cancer progression by upregulating EZH2 and repressing KLF2 transcription.

Min J, Ma J, Wang Q, Yu D Clinics (Sao Paulo). 2022; 77:100081.

PMID: 36087568 PMC: 9468346. DOI: 10.1016/j.clinsp.2022.100081.


A glance at the emerging diagnostic biomarkers in the most prevalent genitourinary cancers.

Alshahrani M Saudi J Biol Sci. 2022; 29(4):2072-2084.

PMID: 35531253 PMC: 9073037. DOI: 10.1016/j.sjbs.2022.01.017.


New Directions and Challenges in Targeted Therapies of Advanced Bladder Cancer: The Role of FGFR Inhibitors.

Szklener K, Chmiel P, Michalski A, Mandziuk S Cancers (Basel). 2022; 14(6).

PMID: 35326568 PMC: 8946699. DOI: 10.3390/cancers14061416.